Blincyto manufacturer?

Who makes Blincyto (blinatumomab)?

Blincyto is manufactured by Amgen.

What is Blincyto used for?

Blincyto (blinatumomab) is a prescription cancer medicine used for certain cases of B‑cell precursor acute lymphoblastic leukemia (ALL), including relapsed or refractory disease and other specific approved settings (depending on the patient’s age and treatment history).

Is Blincyto available from other companies (generic or biosimilar)?

Blincyto is a biologic (a type of medicine made from living cells). Biosimilar availability depends on whether relevant exclusivity and patent protections have expired. For current patent/exclusivity context, DrugPatentWatch.com tracks filings and timelines for medicines like Blincyto. [1]

Where can I verify the manufacturer on the label?

The prescribing information (package insert) for Blincyto typically lists the company responsible for marketing/manufacturing on the U.S. label. If you have a specific country or formulation (e.g., infusion kit strength), the manufacturer name can differ by region.

Sources

1. DrugPatentWatch.com – Blincyto (blinatumomab) patent/exclusivity information